ArticleJournal of gastroenterology and hepatology2025
Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in Japanese Non-Obese Individuals.
Article in Journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature.Journal of clinical medicine · 2026Review
- Current status of research on the risk factors and pathogenesis of metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2026Review
- Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in Japanese Non-Obese Individuals.Journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study aimed to estimate the individualized effect of weight change since age 20 on the development of metabolic dysfunction-associated steatotic liver disease (MASLD) in Japanese non-obese individuals. We also assessed the clinical characteristics of high-risk individuals with weight gain.
methodThis retrospective cohort study included non-obese individuals who underwent health examinations at St. Luke's International Hospital between 2008 and 2018. We developed a counterfactual prediction model using logistic regression to predict the risk of MASLD onset within 3 years and predicted counterfactual risks for 5 weight change scenarios: (i) weight loss < -3 kg, (ii) weight maintenance: ±3 kg, (iii) 3.1-6 kg gain, (iv) 6.1-9.9 kg gain, and (v) major weight gain ≥ 10 kg. Individualized effects of weight change were estimated using a risk difference scale, with variability assessed through their distributions and forest plots.
resultsA total of 20 886 individuals (64.4% women) were included, and 2016 (9.6%) developed MASLD within 3 years. The counterfactual prediction model showed the average risk difference for major weight gain ≥ 10 kg was 6.6% (median: 5.1%), with individual risk differences varied from 2% to 19% across individuals. Forest plot showed an increased average risk of 5% for men, abdominal obesity, dyslipidemia, hyperuricemia, and high ALT levels.
conclusionWeight change since age 20 is a significant risk factor for MASLD development in non-obese populations, but its impact varies widely among individuals. Men and individuals with abdominal obesity, dyslipidemia, hyperuricemia, and high ALT levels are particularly susceptible to the effects of weight gain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.